Recruiting
ETASCAN Project: ETAS Project 2
This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
ClinicalTrials.gov IDNCT07550140
PhaseNA
Enrollment60
SponsorUniversity of Reading
Age60 Years
SexALL
Conditions studied
Cognition, Affect (Mental Function), Sleep, MRI, fMRI, Magnetic Resonance Spectroscopy
About this study
This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
Interventions
- Dietary Supplement: ETAS® — 1500mg ETAS®
- Dietary Supplement: Placebo — Matched placebo capsule
Primary outcomes
- Montreal Cognitive Assessment (MoCA) score (From baseline (pre intervention) to week 12 (post intervention))
- fMRI (From baseline (pre intervention) to week 12 (post intervention))
- MRS (From baseline (pre intervention) to week 12 (post intervention))
Eligibility information
Inclusion Criteria:
* Aging between 60-80 years old
* Having normal vision and hearing
* Having a body mass index between 18.5 and 30
* Having mild to moderate subjective cognitive complaints
Exclusion Criteria:
* Smoking
* Having food allergies
* Following restrictive and/or unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes / No; Are you currently on a weight-reducing or other special diet? Yes/No If 'Yes', please give details.)
* Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders
* Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease
* Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors
* Currently consuming prebiotic or probiotic supplements
* Continuous antibiotic use for \> 3 days within 1 month prior to enrolment
* Continuous use of weight-loss drug for \> 1 month before screening
* Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years
* History of claustrophobia
* Fitted with a pacemaker or artificial heart valve
* Have active implants, such as cochlear, ocular, or penile implant
* Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body
* Drug infusion pump installed
* Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction)
* Have had any surgery that might have involved metal implants
* Current or historical experience of epilepsy
* Have stimulators for nerves, brain or bone installed
* Have an intrauterine contraceptive device installed (IUD)
* Wear transdermal patches containing metal
* Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces
* For scanning, would need to remove coloured contact lenses, nail polish and makeup.
* Hearing aid wearer
* Body piercings that you cannot or will not remove for the scanning session
* Have tattoos or permanent makeup
Study locations
- University of Reading, School of Psychology and Clinical Languages, Reading, Berkshire RG6 6ES United Kingdom
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.